跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BENLYSTA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BENLYSTA
Authorized
STANDARD
BENLYSTA
GlaxoSmithKline Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
55370a7e9279082c
Company
GlaxoSmithKline Inc
Type
Standard
Approval Details
Approval Id
55370a7e9279082c
Drug Approval Canada Name
BENLYSTA
Product Name
BENLYSTA
Status
Marketed
Status Date
2018-05-14
Original Market Date
2018-05-14
Din
02470489
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
90:24.28
Atc Original
L04AG04 BELIMUMAB
Atc Name
l 04 ag 04
Aig Number
0152941003
Company Name
GlaxoSmithKline Inc
Company Address
800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path
/organization/glaxosmithkline-inc
Company Information
Pharmaceutical Company Name
GlaxoSmithKline Inc
Country Name
Canada
Province Name
Ontario
City Name
mississauga,ontario,country_ca
Address
800-100 Milverton Dr
Active Ingredients
BELIMUMAB
200 MG / 1 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
55370a7e9279082c
Type
Standard
Back to Health Canada Approvals